Business Wire

MA-CYTOTRONICS

10.7.2024 08:01:25 CEST | Business Wire | Press release

Share
CytoTronics Breaks Scalability Barriers for Monitoring Live Cell Function, Reveals Pixel Octo for High-Throughput Cell Biology Discovery Applications

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, introduced its high-throughput Pixel™ Octo system at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709748131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CytoTronics is launching its high-throughput Pixel™ Octo system (right) at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo (left), a single plate reader that brings accessibility to researchers. (Photo: Business Wire)

This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo offers full scalability in high-throughput cell biology applications. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo, a single plate reader that brings accessibility to researchers for under US$30,000.

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, and more while generating electrical ‘images’ with single-cell spatial resolution. It dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. Pixel enables new applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Scale up of in vitro cell-based assays is challenging. Traditionally, these screening assays at high scale use hundreds of 96- or 384- well plates to measure simple cellular properties (e.g., "live or dead" screens) to select the most prospective 'hits' of interest, which are then 'scaled down' to verify key effects on cellular functions. Pixel gives researchers a highly sophisticated tool to start key investigations first, get the functional phenotypic assets they cannot get through imaging and other basic techniques, and easily scale these newly developed assays to high-throughput workflows.

The Pixel plate, a proprietary 96-well electronic microplate embedded with custom-designed semiconductor microchips at the base of each well, is at the core of CytoTronics’ Pixel platform. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, enabling thousands of measurements to be taken per well on a single-cell level, on any cell type, spheroid, or 3D organoid system.

In-vitro cell-based assays can initially be developed on Pixel Primo, a single plate reader that can be placed in any standard cell culture incubator. Cell biologists can then scale those assays 8× on Pixel Octo, a self-contained benchtop system complete with a dedicated incubator to regulate temperature, CO2, humidity, and oxygen. Labs can integrate Pixel Octo with industry standard robotic and liquid handling platforms, and multiple systems can be run in parallel for high-throughput applications. Availability of 384-well Pixel plates later in 2024 raises the scalability bar significantly, adding capability to screen tens of thousands of wells simultaneously.

“There’s a tremendous unmet need in cell biology discovery applications to measure the unique cell parameters that Pixel captures. It unlocks new applications and reveals data that scientists haven’t been able to study before,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics. “Pixel Octo takes the power of our unique semiconductor-to-biology interface from assay development in a single plate and unleashes it for high-throughput applications, from exploratory assays on a single Pixel plate to fully validated cell-based applications running at industrial scale.”

“Our early access program for the Pixel Primo kicked off in February and already has 20 global partners spanning biotech, pharmaceutical, academic, cell and organoid providers, and computational biology organizations who are very quickly gaining traction on their applications,” said Duane Sword, Co-Founder and CBO at CytoTronics. “Pixel Octo was designed with scalability in mind and provides cell monitoring and data collection at unprecedented scale. Importantly, Pixel is complementary with imaging and HCS (high content screening) techniques and designed to integrate with standard automation workflows. Pixel is rich with information on biology never seen before, let alone at scale. Hence, we have designed the system with a cloud-centric architecture spanning measurement design, execution, analysis and reporting.”

Through the CytoTronics early access program, customers receive a Pixel Primo, 96-well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software. A starting list price of under $30K (USD) makes it easy for labs to evaluate Pixel as the next frontier of their cell biology research programs.

To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com. You can also visit CytoTronics at ISSCR in Hall H booth #1016 and attend our talks on “Electrical imaging: live cell characterization from stem cell biology to phenotypic disease models”, presented by Shalaka Chitale, CytoTronics’ Director of Biology, Thursday July 11 at 9:10am - 9:20am and Friday July 12 at 6:00pm – 6:30pm.

About Pixel

CytoTronics’ breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well. Pixel Primo and Octo offer simultaneous monitoring of cells across all wells of either a single Pixel plate or eight at the same time. Cloud-based Pixel Pro software enables applications across multiple cell types and organoids with cloud-based control and interactive analysis of the data-rich, live cell measurements collected.

About CytoTronics

At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709748131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Beacon Acquires Haize Labs to Power AI for the Real Economy17.9.2026 16:30:00 CEST | Press release

Haize Labs leadership will anchor Beacon’s new applied AI research group, accelerating the deployment of AI across the essential businesses Beacon owns Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry. The addition of the Haize Labs team will strengthen th

TIMELAB Develops OEM/ODM Hair Straightener Reaching 200°C at All Three Measured Points in 15 Seconds17.9.2026 16:00:00 CEST | Press release

Testing at 230 V with a 260°C setting confirmed at least 200°C after 15 seconds at all three measured plate locations (front, center and rear), not just a single point. TIMELAB Co., Ltd., a Japanese beauty-appliance OEM/ODM provider, has developed a hair straightener for OEM/ODM customization for international hair care brands and professional markets. In testing at 230 V with a 260°C setting, all three measured plate locations reached at least 200°C after 15 seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914187865/en/ Three-Point Plate Testing A European-market development unit with a maximum setting of 260°C was tested at 230 V. Fifteen seconds after power-on, readings at the front, center and rear were 212.5°C, 227.5°C and 200.0°C, respectively. From around 60 seconds onward, temperature differences among the three points narrowed, indicating a stable trend. Precision Temperature Control An NTC sensor inside t

Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 15:09:00 CEST | Press release

Agent Hub, part of Earnix AIOS, brings more than 25, insurance-specific agents and apps into Earnix’s governed pricing, underwriting, and customer decision solutions- improving workflows and business performance Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and i

Medisca Launches Global Peptide Division17.9.2026 15:07:00 CEST | Press release

New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation. For Medisca, the opportunity is familiar. More than 35 years ago, the company was founded t

Elliptic Launches Its Decode Agent to Answer On-Chain Risk Questions and Shows Its Work17.9.2026 15:00:00 CEST | Press release

Hours of tracing, answered in seconds, with the evidence attached Elliptic, the global leader in on-chain risk, today launched Decode, an AI agent built on Elliptic’s intelligence platform. The Decode agent answers natural-language questions about cryptoasset addresses and their exposure in seconds, and returns the evidence behind every answer. Compliance and investigations teams need answers to questions nobody planned for. Getting them out of the data is now a specialist skill, so the questions wait for someone who has it, or go unasked. Meanwhile illicit actors move at machine speed, and agents are starting to sit on both sides of a payment. General-purpose AI assistants can produce an answer. They cannot show where it came from. A fluent response with nothing behind it cannot be put in front of a second-line reviewer, an auditor, or a regulator. “The market is full of AI that asks to be trusted. That is not good enough when someone asks how you reached a decision,” said Jackson Hul

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye